PsA

Psa image

▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk for the UK and hpra.ie/homepage/about-us/report-an-issue for Republic of Ireland. Adverse events should also be reported to UCB Pharma Ltd at ucbcares.uk@ucb.com  or 0800 2793177 for the UK and UCB (Pharma) Ireland Ltd at ucbcares.ie@ucb.com or 1800 930075 for Republic of Ireland.

NICE recommendation
BIMZELX DELIVERED HIGH TREATMENT TARGETS IN PsA 1-4

BIMZELX® (bimekizumab) is indicated for the treatment of: active PsA, alone or in combination with methotrexate, in adults who have had an inadequate response or who have been intolerant to one or more DMARDs; active nr-axSpA, in adults with objective signs of inflammation as indicated by elevated CRP and/or MRI, who have responded inadequately or are intolerant to NSAIDs; and active AS, in adults who have responded inadequately or are intolerant to conventional therapy.3

BIMZELX DELIVERED EFFICACY, SUSTAINED OVER TIME IN PATIENTS WITH PsA (TO WEEK 52) 1–4

 

In two pivotal phase III trials, 43.9% (n=189/431) of biologic-naïve and 43.4% (n=116/267) of TNFi-inadequate responder patients achieved the primary endpoint of ACR 50 at Week 16 with BIMZELX (versus 10.0% [n=28/281] and 6.8% [n=9/133] with placebo, respectively; (p<0.0001 and p<0.001 for each trial respectively)1-3

Joint Efficacy 
BIMZELX PROVIDED SUSTAINED EFFICACY IN THE JOINTS, CONSISTENTLY ACROSS BIOLOGIC-NAIVE and TNFi-IR PATIENTS, AS MEASURED BY ACR 501,2,4,5

 

Primary endpoint in both trials: ACR 50 at Week 16 (p<0.0001 vs placebo)1,2

 

 ACR 50 was achieved by 43.9% (189/431) of biologic-naïve and 43.4% (116/267) of TNFi-IR patients with PsA at Week 16 (primary endpoint in BE OPTIMAL and BE COMPLETE),1–3 54.5% (235/431) and 51.7% (138/267) at Week 52 respectively (NRI analysis).4,5 ASAS 40 was achieved by 47.7% (61/128) of nr-axSpA patients and 44.8% (99/221) of AS patients at Week 16, (primary endpoint in BE MOBILE 1/2);6 60.9% (78/128) and 58.4% (129/221) at Week 52, respectively (NRI analysis).3,6 Rapid onset was demonstrated by numerically higher responder rates (ACR 50) observed when compared with placebo at Week 4 in BE OPTIMAL, 17.6% (76/431), versus 3.2% (9/281); and BE COMPLETE, 16.1% (43/267) versus 1.5% (2/133) respectively.1,2 Rapid separation in ASAS 40 response rates was observed within 1–2 weeks after single a dose of BIMZELX versus placebo; 16.4% (21/128) versus 1.6% (2/126) at Week 1 in BE MOBILE 1, and 16.7% (37/221) versus 7.2% (8/111) at Week 2 in BE MOBILE 2 (NRI analysis).7,8 Reduction of patient limitations was demonstrated using MDA in PsA and ASDAS <2.1 in axSpA. MDA was achieved by 45.0% (194/431) of biologic-naïve and 44.2% (118/267) TNFi-IR patients with PsA at Week 16 (NRI analysis).3 ASDAS <2.1 was achieved by 46.1% (59/128) of nr-axSpA patients and 44.8% (99/221) of AS patients at Week 16, BE MOBILE 1 and BE MOBILE 2 respectively (exploratory endpoint, MI analysis).3

 

 

After Week 16, patients in BE OPTIMAL and BE COMPLETE were aware that they were receiving active treatment, which may have affected the results. Week 52 data are for patients who completed the BE COMPLETE phase III trial (which ran for 16 weeks) and then entered the BE VITAL open-label extension study.1,2,4

 

 

After Week 16, patients in BE OPTIMAL and BE COMPLETE were aware that they were receiving active treatment, which may have affected the results. Week 52 data are for patients who completed the BE COMPLETE phase III trial (which ran for 16 weeks) and then entered the BE VITAL open-label extension study.1,2,4

 

*In BE OPTIMAL, ACR 50 was achieved by 17.6% (n=76/431) at Week 4 (vs 3.2% n=9/281 with placebo), 43.9% (n=189/431) at Week 16 (vs 10.0% [n=28/281] with placebo, p<0.0001), and 54.5% (n=235/431) at Week 52 of biologic-naïve patients in the BIMZELX treatment arm (NRI analysis).1,5 In BE COMPLETE, ACR 50 was achieved by 16.1% (n=43/267) at Week 4 (vs 1.5% [n=2/133] with placebo), 43.4%(n=116/267) at Week 16 (vs 6.8% [n=9/133] with placebo, p<0.0001), and 51.7% (n=138/267) at Week 52 of TNFi-IR patients in the BIMZELX treatment arm (NRI analysis);2,4 **90.0% (n=388/431) of patients who completed 16 weeks of treatment remained on BIMZELX at Week 52;5 †In BE OPTIMAL, mean vdHmTSS change from baseline was 0.01 at Week 16 (vs 0.36 with placebo) and 0.08 at Week 52 in the overall population BIMZELX treatment arm (n=365; NRI analysis).,5 ‡BIMZELX is approved for Q4W/Q8W dosing with PsA in coexisting moderate-to-severe plaque psoriasis.3

Skin Efficacy

 

BIMZELX PROVIDED SUSTAINED ALMOST COMPLETE OR COMPLETE SKIN CLEARANCE, AS MEASURED BY PASI 90 OR PASI 100 (TO WEEK 52)*1,2,4,5

 

After Week 16 all patients were aware that they were receiving active treatment, which may have affected the results. Week 52 data are for patients who completed the BE COMPLETE phase III trial (which ran for 16 weeks) and then entered the BE VITAL open-label extension study

After Week 16 all patients were aware that they were receiving active treatment, which may have affected the results. Week 52 data are for patients who completed the BE COMPLETE phase III trial (which ran for 16 weeks) and then entered the BE VITAL open-label extension study.

After Week 16 all patients were aware that they were receiving active treatment, which may have affected the results. Week 52 data are for patients who completed the BE COMPLETE phase III trial (which ran for 16 weeks) and then entered the BE VITAL open-label extension study.

 

After Week 16 all patients were aware that they were receiving active treatment, which may have affected the results. Week 52 data are for patients who completed the BE COMPLETE phase III trial (which ran for 16 weeks) and then entered the BE VITAL open-label extension study.

 

*In BE OPTIMAL at Week 16: PASI 90 was achieved by 61.3% (n=133/217) with BIMZELX and 2.9% (n=4/140) with placebo, and PASI 100 was achieved by 47.5% (n=103/217) with BIMZELX and 2.1% (n=3/140) with placebo; at Week 52: PASI 90 was achieved by 71.4% (n=155/217) and PASI 100 was achieved by 60.8% (n=132/217) of patients in the BIMZELX treatment arm (NRI analysis).1,5 In BE COMPLETE, at Week 16: PASI 90 was achieved by 68.8%% (n=121/176) with BIMZELX and 6.8% (n=6/88) with placebo, and PASI 100 (additional efficacy outcome) was achieved by 58.5% (n=103/176) with BIMZELX and 4.5% (n=4/88) with placebo; at Week 52: PASI 90 was achieved by 74.4% (n=131/176) and PASI 100 was achieved by 65.9% (n=116/176) of patients in the BIMZELX treatment arm (NRI analysis);2,4 **PASI response in patients with psoriasis involving at least 3% BSA at baseline.1,2,4,5 †BIMZELX is approved for Q4W/Q8W dosing with PsA in coexisting moderate-to-severe plaque psoriasis.3

‡ For some patients with plaque psoriasis (including psoriatic arthritis with coexistent moderate to severe psoriasis) and a body weight ≥ 120 kg who did not achieve complete skin clearance at week 16, 320 mg every 4 weeks after week 16 may further improve treatment response.3

Disease Activity
BIMZELX DELIVERED SUSTAINED EFFICACY ACROSS MULTIPLE DISEASE DOMAINS, AS MEASURED BY MDA (TO WEEK 104)*1,2,4,5,15-17

 

 

After Week 16, patients in BE OPTIMAL and BE COMPLETE were aware that they were receiving active treatment, which may have affected the results. Week 52 data are for patients who completed the BE COMPLETE phase III trial (which ran for 16 weeks) and then entered the BE VITAL open-label extension study.

 

After Week 16, patients in BE OPTIMAL and BE COMPLETE were aware that they were receiving active treatment, which may have affected the results. Week 52 data are for patients who completed the BE COMPLETE phase III trial (which ran for 16 weeks) and then entered the BE VITAL open-label extension study.

 

*In BE OPTIMAL, MDA was achieved by 23.4% (n=99/431) at Week 4 (vs 6.8% [n=19/281] with placebo),5 45.0% (n=194/431) at Week 16 (vs 13.2% [n=37/281] with placebo, p<0.0001), 55.0% (n=237/431) of patients in the BIMZELX treatment arm at Week 52,1,15 and 52.4% (n=226/431) of patients in the BIMZELX treatment arm at Week 104 (NRI analysis).16 In BE COMPLETE, MDA was achieved by 17.2% (n=46/267) at Week 4 (vs 4.5% [n=6/133] with placebo),17 44.2% (n=118/267) at Week 16 (vs 6.0% [n=8/133] with placebo, p<0.0001), 47.2% (n=126/267) of patients in the BIMZELX treatment arm at Week 522,4 and 44.9% (n=120/267) of patients in the BIMZELX treatment arm at Week 100 (NRI analysis).16 **BIMZELX is approved for Q4W/Q8W dosing with PsA in coexisting moderate-to-severe plaque psoriasis.3

psa-mda-explained01
9. Safety profile

After Week 16, patients in BE OPTIMAL, BE COMPLETE, BE MOBILE 1 and BE MOBILE 2 were aware that they were receiving active treatment, which may have affected the results. *Week 52 data are from patients who completed BE COMPLETE and entered the BE VITAL open-label extension study.4 Week 52 data are from BE MOBILE 1 and BE MOBILE 2 and are the open-label maintenance phase of the studies.9 **Includes patients who switched from BIMZELX Q4W (events reports after the switch only).5,16 †One death occurred in a patient receiving BIMZELX due to a motorcycle accident.5 ‡One sudden death occurred in a patient with a history of cardiac events.4 ¥One death due to acute myocardial infarction, reported as unrelated to the study drug.16 §Malignancies excluding non-melanoma skin cancer.16

BIMZELX DOSING FOR PATIENTS WITH PsA3

 

           HOW TO USE

 

 

dosingPNG

* The recommended dose for adult patients with active psoriatic arthritis is 160 mg (given as one subcutaneous injection of 160 mg) every 4 weeks. Consideration should be given to discontinuing treatment in patients who have shown no improvement by 16 weeks of treatment;3 **The recommended dose for adult patients with psoriatic arthritis and coexistent moderate-to-severe plaque psoriasis is the same as for plaque psoriasis, 320 mg (given as two subcutaneous injections of 160 mg each) at Week 0, 4, 8, 12, 16, and every 8 weeks thereafter. Consideration should be given to discontinuing treatment in patients who have shown no improvement by 16 weeks of treatment.3 †If a sufficient clinical responsed in the joints cannot be maintained after Week 16, a switch to 160 mg Q4W can be considered.3 

Pivotal phase III study design: BE OPTIMAL
 

Biologic-naïve patients with active PsA21

BE OPTIMAL

Adapted from McInnes IB, et al. Lancet. 2023;401:25-77. Supplementary appendix.

Pivotal phase III study design: BE COMPLETE

 

TNFi-inadequate responder patients with active PsA22

BE COMPLETE

Adapted from Merola JF, et al. Lancet. 2023;401:38-48. Supplementary appendix.

Phase IIb and open-label extension study design: BE ACTIVE23

 

BE ACTIVE

Adapted from Coates LC. et al. Arthritis Rheumatol. 2022;74:1959-1970. Supplementary appendix

Abbreviations

ACR 50, ≥50% response in the American College of Rheumatology criteria; AS, ankylosing spondylitis; ASAS 40, ≥40% improvement in the Assessment of SpondyloArthritis International Society criteria; ASDAS, Ankylosing Spondylitis Disease Activity Score; axSpA, axial spondyloarthritis; BSA, body surface area; CRP, c-reactive protein; DMARDs, disease-modifying antirheumatic drugs; HS, hidradenitis suppurativa; IL, interleukin; MHRA, Medicines and Healthcare products Regulatory Agency; MI, multiple imputation; MOA, mechanism of action; MRI, magnetic resonance imaging; nr-axSpA, non-radiographic axial spondyloarthritis; NRI, non-responder imputation; NSAIDs, non-steroidal anti-inflammatory drugs; PASI, Psoriasis Area and Severity Index; PASI 90, >90 improvement from baseline in Psoriasis Area Severity Index; PsA, psoriatic arthritis; r-axSpA, radiographic axial spondyloarthritis; TNFi-IR, tumour necrosis factor inhibitor-inadequate response.

References

  1. McInnes, I. B., Asahina, A., Coates, L. C., Landewé, R., Merola, J. F., Ritchlin, C. T., Tanaka, Y., Gossec, L., Gottlieb, A. B., Warren, R. B., Ink, B., Assudani, D., Bajracharya, R., Shende, V., Coarse, J., & Mease, P. J. (2023). Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL). The Lancet, 401(10370), 25–37.
  2. Merola, J. F., Landewé, R., McInnes, I. B., Mease, P. J., Ritchlin, C. T., Tanaka, Y., Asahina, A., Behrens, F., Gladman, D. D., Gossec, L., Gottlieb, A. B., Thaçi, D., Warren, R. B., Ink, B., Assudani, D., Bajracharya, R., Shende, V., Coarse, J., & Coates, L. C. (2023). Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE). The Lancet, 401(10370), 38–48.
  3. UCB Pharma Limited. (2025). Bimzelx - Summary of Product Characteristics. Medicines.org.uk. https://www.medicines.org.uk/emc/product/12833/smpc [Accessed September 2025]
  4. Coates, L. C., Landewé, R., McInnes, I. B., Mease, P. J., Ritchlin, C. T., Tanaka, Y., Asahina, A., Behrens, F., Gladman, D. D., Gossec, L., Orbai, A.-M., Gottlieb, A. B., Warren, R. B., Ink, B., Bajracharya, R., Shende, V., Coarse, J., & Merola, J. F. (2024). Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL. RMD Open, 10(1), e003855.
  5. Ritchlin, C. T., Coates, L. C., McInnes, I. B., Mease, P. J., Merola, J. F., Tanaka, Y., Asahina, A., Gossec, L., Gottlieb, A. B., Warren, R. B., Ink, B., Bajracharya, R., Shende, V., Coarse, J., & Landewé, R. B. (2023). Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study. Annals of the Rheumatic Diseases, 82(11), 1404–1414.
  6. van der Heijde, D., Deodhar, A., Baraliakos, X., Brown, M. A., Dobashi, H., Dougados, M., Elewaut, D., Ellis, A. M., Fleurinck, C., Gaffney, K., Gensler, L. S., Haroon, N., Magrey, M., Maksymowych, W. P., Marten, A., Massow, U., Oortgiesen, M., Poddubnyy, D., Rudwaleit, M., … Xu, H. (2023). Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials. Annals of the Rheumatic Diseases, 82(4), 515–526.
  7. UCB. (2023). AS0010 Clinical Study Report - BE MOBILE. UCB Data on File.
  8. UCB. (2023). AS0011 Clinical Study Report - BE MOBILE. UCB Data on File.
  9. Baraliakos, X., Deodhar, A., van der Heijde, D., Magrey, M., Maksymowych, W. P., Tomita, T., Xu, H., Massow, U., Fleurinck, C., Ellis, A. M., Vaux, T., Shepherd-Smith, J., Marten, A., & Gensler, L. S. (2024). Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies. Annals of the Rheumatic Diseases, 83(2), 199–213.
  10. van der Heijde, D., Gladman, D. D., Kavanaugh, A., & Mease, P. J. (2020). Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research. Arthritis Research & Therapy, 22(1), 18.
  11. Merola, J. F., Lockshin, B., & Mody, E. A. (2017). Switching biologics in the treatment of psoriatic arthritis. Seminars in Arthritis and Rheumatism, 47(1), 29–37.
  12. Furst, D. E., & Louie, J. S. (2019). Targeting inflammatory pathways in axial spondyloarthritis. Arthritis Research & Therapy, 21(1), 135.
  13. Manica, S. R., Baraliakos, X., & Nikiphorou, E. (2020). Early Recognition and Treatment of Spondyloarthritis: A Timeless Challenge. European Medical Journal. Rheumatology, 7(1), 72–79.
  14. Wilson, N., Liu, J., Adamjee, Q., Di Giorgio, S., Steer, S., Hutton, J., & Lempp, H. (2023). Exploring the emotional impact of axial Spondyloarthritis: a systematic review and thematic synthesis of qualitative studies and a review of social media. BMC Rheumatology, 7(1), 26.
  15. Gudu, T., & Gossec, L. (2018). Quality of life in psoriatic arthritis. Expert Review of Clinical Immunology, 14(5), 405–417.
  16. James, L., Hailey, L. H., Suribhatla, R., McGagh, D., Amarnani, R., Bundy, C. E., Kirtley, S., O’Sullivan, D., Steinkoenig, I., White, J. P. E., Vivekanantham, A., & Coates, L. C. (2024). The impact of psoriatic arthritis on quality of life: a systematic review. Therapeutic Advances in Musculoskeletal Disease, 16, 1759720X241295920.
  17. Espahbodi, S., Bassett, P., Cavill, C., Freeth, M., Hole, J., & Sengupta, R. (2017). Fatigue contributes to work productivity impairment in patients with axial spondyloarthritis: a cross-sectional UK study. Clinical and Experimental Rheumatology, 35(4), 571–578.
  18. UCB. (2025). axSpA Quantitative Report. UCB Data on File.
  19. UCB. (2025). PsA Quantitative Study. UCB Data on File.
  20. Connolly, D., Fitzpatrick, C., & O’Shea, F. (2019). Disease activity, occupational participation, and quality of life for individuals with and without severe fatigue in ankylosing spondylitis. Occupational Therapy International, 2019, 3027280.
  21. Navarro-Compán, V., Sepriano, A., El-Zorkany, B., & van der Heijde, D. (2021). Axial spondyloarthritis. Annals of the Rheumatic Diseases, 80(12), 1511–1521.
  22. Tucker, L., Allen, A., Chandler, D., Ciurtin, C., Dick, A., Foulkes, A., Gullick, N., Helliwell, P., Jadon, D., Jones, G., Kyle, S., Madhok, V., McHugh, N., Parkinson, A., Raine, T., Siebert, S., Smith, C., Tillett, W., & Coates, L. C. (2022). The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs. Rheumatology (Oxford, England), 61(9), e255–e266.
  23. Zhao, S. S., Harrison, S. R., Thompson, B., Yates, M., Eddison, J., Chan, A., Clarke, N., Corp, N., Davis, C., Felix, L., Flora, K., Gregory, W. J., Jones, G. T., Lamb, C. A., Marzo-Ortega, H., Murphy, D. J., Petrushkin, H., Sandhu, V., Sengupta, R., … Gaffney, K. (2025). The 2025 British Society for Rheumatology guideline for the treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs. Rheumatology (Oxford, England), 64(6), 3242–3254.
  24. Bimekizumab for treating axial spondyloarthritis. (2023). NICE. Retrieved September 11, 2025, from https://www.nice.org.uk/guidance/ta918 [Accessed September 2025]
  25. Bimekizumab for treating active psoriatic arthritis. (2023). NICE. Retrieved September 11, 2025, from https://www.nice.org.uk/guidance/ta916 [Accessed September 2025]
  26. Ogdie, A., Ye, X., Saffore, C. D., Parikh, B., Iyile, T., Blachley, T., Eliot, M., Middaugh, N., & Mease, P. J. (2024). Ab0869 real-world burden of uncontrolled disease despite treatment with tumor necrosis factor inhibitors among axial spondyloarthritis patients in the corevitas psoriatic arthritis/spondyloarthritis registry. Scientific Abstracts, 83, 1735–1735.
  27. Mease, P. J., Ye, X., Saffore, C. D., Parikh, B., Ciecinski, S., Blachley, T., Eliot, M., Middaugh, N., & Ogdie, A. (2024). Pos0989 real-world burden of uncontrolled disease despite treatment with tumor necrosis factor inhibitors among psoriatic arthritis patients in the corevitas psoriatic arthritis/spondyloarthritis registry. Scientific Abstracts, 83, 687–688.
  28. Caporali, R., Conti, F., & Iannone, F. (2023). Management of patients with inflammatory rheumatic diseases after treatment failure with a first tumour necrosis factor inhibitor: A narrative review. Modern Rheumatology, 34(1), 11–26.
  29. Coates, L. C., McInnes, I. B., Merola, J. F., Warren, R. B., Kavanaugh, A., Gottlieb, A. B., Gossec, L., Assudani, D., Bajracharya, R., Coarse, J., Ink, B., & Ritchlin, C. T. (2022). Safety and efficacy of bimekizumab in patients with active psoriatic arthritis: Three-year results from a phase IIb randomized controlled trial and its open-label extension study. Arthritis & Rheumatology, 74(12), 1959–1970.
  30. Deodhar, A., Navarro-Compán, V., Poddubnyy, D., Gensler, L. S., Ramiro, S., Tomita, T., Marzo-Ortega, H., Fleurinck, C., Vaux, T., Massow, U., de Peyrecave, N., van der Heijde, D., & Baraliakos, X. (2025). Long-term safety and sustained efficacy of bimekizumab in patients with ankylosing spondylitis (radiographic axial spondyloarthritis): 5-year results from BE AGILE (phase 2b) and its open-label extension. RMD Open, 11(1), e005081.
  31. Mease, P. J., Merola, J. F., Tanaka, Y., Gossec, L., McInnes, I. B., Ritchlin, C. T., Landewé, R. B. M., Asahina, A., Ink, B., Heinrichs, A., Bajracharya, R., Shende, V., Coarse, J., & Coates, L. C. (2024). Safety and efficacy of bimekizumab in patients with psoriatic arthritis: 2-year results from two phase 3 studies. Rheumatology and Therapy, 11(5), 1363–1382.
  32. Baraliakos, X., Deodhar, A., Van der Heijde, D., Van den Bosch, F., Magrey, M., Maksymowych, W. P., Tomita, T., Xu, H., Massow, U., Fleurinck, C., Vaux, T., Prajapati, C., Shepherd-Smith, J., Marten, A., & Gensler, L. S. (2024). Pos0806 long-term sustained efficacy and safety of bimekizumab across the full spectrum of axial spondyloarthritis: 2-year results from two phase 3 studies. Scientific Abstracts, 83, 913–914.
  33. Baraliakos, X., Deodhar, A., van der Heijde, D., van den Bosch, F., Magrey, M., Maksymowych, W. P., Tomita, T., Xu, H., Voiniciuc, D., Prajapati, C., Manente, M., Marten, A., & Gensler, L. S. (2025). Bimekizumab demonstrated sustained efficacy and safety across the full spectrum of axial spondyloarthritis: 3-year results from two phase 3 studies and their open-label extension. EULAR.
  34. Gensler, L. S., Marzo-Ortega, H., Taieb, V., Voiniciuc, D., Marten, A., Stojan, G., Kim, M., & Rudwaleit, M. (2024). Achievement of Remission Defined by Abscence of Objective Signs of Inflammation versus ASDAS ID in Patients with Active Axial Spondyloarthritis Treated with Bimekizumab: 52-Week Results from Two Phase 3 Studies. American College of Rheumatology.
  35. Baraliakos, X., Deodhar, A., van der Heijde, D., Van den Bosch, F., Magrey, M., Maksymowych, W. P., Tomita, T., Xu, H., Massow, U., Vaux, T., Prajapati, C., Manente, M., Marten, A., & Gensler, L. S. (2025). Long-term safety and efficacy of bimekizumab in axial spondyloarthritis: 2-year results from two phase 3 studies. Rheumatology (Oxford, England), 64(6), 3534–3546.
  36. Navarro-Compán, V., Kiltz, U., Mease, P. J., Dubreuil, M., Gaffney, K., Deodhar, A., de la Loge, C., Voiniciuc, D., Coarse, J., & Marzo-Ortega, H. (2025). Sustained Improvements with Bimekizumab in Pain, Morning Stiffness, Fatigue, Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: 3-Year Results from Two Phase 3 Studies. EULAR.
  37. Rudwaleit, M., Navarro-Compán, V., Deodhar, A., Dubreuil, M., Mørup, M. F., Taieb, V., de la Loge, C., Fleurinck, C., Massow, U., Vaux, T., & Boonen, A. (2025). Work productivity improved in patients with axial spondyloarthritis receiving bimekizumab treatment over 52 weeks: Results from two phase 3 studies.
  38. van der Horst-Bruinsma, I. E., Brown, M. A., van Gaalen, F., Haroon, N., Gensler, L. S., Marten, A., Manente, M., Stojan, G., Vaux, T., White, K., Deodhar, A., & Rudwaleit, M. (2024, September 1). Low Uveitis Rates in Patients with Axial Spondyloarthritis or Psoriatic Arthritis Treated with Bimekizumab: Long-Term Results from Phase 2b/3 Trials. ACR Meeting Abstracts.
  39. McInnes, I. B., Merola, J. F., Coates, L. C., Gossec, L., Landewé, R., Proft, F., Tanaka, Y., Asahina, A., Ink, B., Bajracharya, R., Coarse, J., & Mease, P. J. (2025). Dual inhibition of IL-17A and IL-17F with bimekizumab demonstrated long-term safety and efficacy in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: Final 3-year results from the phase 3 BE COMPLETE study and its open-label extension. EULAR.
  40. Gossec, L., Coates, L. C., McInnes, I. B., Mease, P. J., Ritchlin, C. T., Tanaka, Y., Asahina, A., Ink, B., Bajracharya, R., Coarse, J., & Merola, J. F. (2025). Bimekizumab, a dual inhibitor of IL-17A and IL-17F, demonstrated long-term safety and efficacy in biologic DMARD-naïve patients with active psoriatic arthritis: Final 3-year results from the phase 3 BE OPTIMAL study and its open-label extension. EULAR.
logo

IE-BK-2400114

Date of creation: November 2024